Clinical trials
Immunity clinical trials
Below are recruiting immunity clinical trials, each written for real people, not researchers. We’re tracking 1,011 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05858632RecruitingPhase 4
Study immune patterns during guselkumab skin response in psoriasis
This trial studies how the immune system changes in the skin after guselkumab treatment for psoriasis, including the scalp. You may be asked to meet certain scalp severity and medication safety rules.
San Francisco, CaliforniaAges 18 years+ - NCT05749627Recruiting
Vaccine for advanced cancers using your tumor’s targets
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
Nanchang, JiangxiAges 18–70 - NCT05732779Recruiting
App-based check-ins to help teens take transplant medicines
This study tests a phone app that uses video check-ins (called directly observed therapy) to help adolescent heart-transplant patients take their immunosuppression medicines as prescribed. It may help reduce missed doses, which is important for protecting the transplanted heart.
Coral Gables, FloridaAges 10–21 - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT05481658RecruitingPhase 1
DPCP plus immunotherapy for skin cancer spread to the skin
This Phase 1 study tests a skin-applied treatment called DPCP added to standard PD-1/PD-L1 immunotherapy for cancers that have spread to the skin. It aims to improve control of skin tumors while checking safety and how well the immune system responds.
New York, New YorkAges 18 years+ - NCT05520892RecruitingPhase 4
IVIG dose options for newly diagnosed childhood ITP
This study compares two intravenous (IV) IgG treatment regimens for children newly diagnosed with immune thrombocytopenia (ITP). It aims to find a regimen that works well and is safe for raising low platelet counts.
Fuzhou, FujianAges 4 weeks–14 years - NCT05570552Recruiting
Testing health impacts in adults from smoky, arsenic-exposed homes
This study follows adults who took part in an earlier GEOHEALTH study and live in homes that use traditional stoves, with low-to-moderate arsenic exposure in drinking water. It aims to understand how these environmental factors affect health, and what changes might be possible.
DhakaAges 25–70 - NCT04840355Recruiting
Monitoring safety of sintilimab in Chinese patients
This study carefully tracks how safe sintilimab is for people with cancer in real-world care. It may help your care team understand side effects and risks during treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT05334888Recruiting
Study how sex and gut bacteria relate to heart risk
This study follows people over time to understand how sex-related factors and gut bacteria may affect heart and blood-vessel risk. It may help researchers identify who could benefit from earlier prevention, based on personal risk patterns.
BerlinAges 18–50 - NCT04375657RecruitingPhase 2
Study to restore thymus function and improve insulin control
This Phase 2 study tests a treatment aimed at improving immune system function and reducing insulin problems over 12 months. You may be able to join if you’re between 40 and 80 and don’t have certain diabetes, hormonal, heart, or immune conditions.
Torrance, CaliforniaAges 40–80 - NCT05655273Enrolling by invitationPhase 4
Switch tacrolimus timing after liver transplant to Envarsus
This trial looks at whether changing your maintenance anti-rejection medicine from Prograf (usually twice daily) to Envarsus (once daily) can help keep your liver and kidney function stable. It targets people who may be having kidney side effects, symptoms from tacrolimus, or trouble taking a twice-daily medicine.
Toronto, OntarioAges 18–99 - NCT04476563Recruiting
Study liver injury from checkpoint cancer immunotherapy
This study looks at why some people develop liver inflammation after checkpoint inhibitor cancer treatment, called checkpoint inhibitor–induced liver injury (ChILI). It compares people with ChILI to similar cancer patients who are starting the same type of immunotherapy, to better understand and track these liver injury events.
NottinghamAges 18 years+ - NCT04517656Recruiting
Testing blood markers after a bone marrow donor transplant
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Saint-EtienneAges 18 years+ - NCT04083183RecruitingPhase 1/Phase 2
Testing radiation plus antibody therapy for certain non-cancer diseases
This early-phase study tests a conditioning treatment using total-body irradiation and a radioactive antibody (called astatine-211) before a stem cell transplant for non-cancer conditions. The goal is to improve how well the donor cells take hold and are tolerated.
Seattle, WashingtonAges 18–49 - NCT04517838Recruiting
Testing immune responses to anti-HER2 breast cancer treatments
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
Jacksonville, FloridaAges 18 years+ - NCT03875703Recruiting
Biology sample collection after routine vaccination
This study collects biological samples (like blood and/or other samples) after you get a routine vaccine. It helps researchers learn more about how vaccines affect the body.
CréteilAges 18 years+ - NCT04571203RecruitingPhase 1
Kidney transplant plus blood-cell treatment to help the graft settle
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
Palo Alto, CaliforniaAges 18–65 - NCT04392401Recruiting
Study immune changes in adults during ICU stay for COVID-19
This study looks at how your immune system responds while you’re in the intensive care unit (ICU) for COVID-19. Researchers will collect samples early in the ICU stay to better understand immune changes during the illness.
BronAges 18 years+ - NCT04402788RecruitingPhase 2/Phase 3
Radiation added to immune therapy for extensive small cell lung cancer
This trial tests whether adding radiation therapy to standard immune therapy (atezolizumab) after initial chemo can help people with extensive-stage small cell lung cancer live longer and control the cancer better. You must have a good response (partial response) or stable disease after initial treatment, plus several lab/imaging checks to confirm safety.
Birmingham, AlabamaAges 18 years+ - NCT06821100RecruitingPhase 1
Thymalfasin to Boost COVID-19 Vaccine Response in Older Adults
This trial tests whether a drug called thymalfasin (thymosin alpha 1) can help older adults (65+) get a stronger immune response from their COVID-19 booster shot. It may be especially helpful for those whose immune systems have weakened with age.
Houston, TexasAges 65–100 - NCT03357172Recruiting
Study immune changes after a stem cell transplant
This study looks at how the immune system changes after an allogeneic stem cell transplant (using a donor’s stem cells). It may help researchers understand what controls immune recovery and transplant-related complications.
Vandœuvre-lès-NancyAges 18 years+ - NCT05351216Recruiting
Sirolimus safety with routine vaccines for a rare blood vessel tumor
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
Shanghai, Shanghai MunicipalityAges Up to 12 years - NCT05365672RecruitingPhase 2
Donor immune cell therapy during live kidney transplant
This Phase 2 trial studies a treatment using immune cells made from your living donor, given around the time of kidney transplant. It aims to improve transplant safety and outcomes by adjusting the immune response to the new kidney.
BerlinAges 18–69 - NCT07132112RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune disease
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
Nantong, JiangsuAges 18–65
Hear when a new Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunity?
- Yes. Clin2 currently lists 1,011 recruiting immunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.